Related Experiment Videos
Expression and phorbol ester-induced down-regulation of protein kinase C isozymes in osteoblasts
1Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, Illinois, USA.
Abstract:
The protein kinase C (PKC) enzyme family consists of at least 11 isozymes in three classes, with characteristic tissue distributions. Phorbol esters activate and ultimately down-regulate phorbol-sensitive isozymes. PKC is a signal transducer in bone, and phorbol esters influence bone resorption. Little is known about specific PKC isozymes in this tissue, however. We describe here the expression and phorbol ester-induced down-regulation of PKC isozymes in osteoblasts. Normal mouse osteoblasts and seven osteoblastic cell lines (rat UMR-106, ROS 17/2.8, ROS 24/1, and human MG-63, G-292, SaOS-2, HOS-TE85) were screened for isozyme expression by Western immunoblotting using isozyme-specific anti-PKC antibodies. The conventional alpha and beta I isozymes, but not gamma, were present in each of the osteoblasts examined; PKC-beta II was detectable in all but the ROS 24/1 line. PKC-epsilon was expressed in all osteoblasts screened, but other novel PKCs, delta, eta, and theta, were detectable only in select lines. The atypical zeta and iota/lambda PKCs were in all osteoblasts examined. To determine the sensitivity of the isozymes to prolonged phorbol ester treatment, normal osteoblasts and the UMR-106 cell line were treated with vehicle or 1 microM phorbol 12, 13-dibutyrate (PDB) for 1, 3, 6, 12, 24, or 48 h, and Western blot analysis was performed. Normal and UMR-106 cells showed similar phorbol sensitivities; conventional (alpha, beta I) and novel (delta, epsilon, eta) isozymes were down-regulated by prolonged phorbol treatment but atypical isozymes were not. Down-regulation of all sensitive PKCs was detectable within 6 h of phorbol treatment; the novel delta and epsilon isozymes, however, showed more rapid and dramatic down-regulation than conventional isozymes. The observed down-regulation was dose-dependent (0.3-3 microM) and specific; 48 h treatment with the inactive phorbol, 4 alpha-phorbol 12,13-didecanoate (4 alpha-PDD), failed to down-regulate PDB-sensitive isozymes. The phorbol-induced down-regulation was also reversible; 24 h after withdrawing PDB, all phorbol-sensitive isozymes, except PKC-eta, had recovered at least partially. These studies, the first to characterize thoroughly PKC isozyme expression in osteoblastic cells from several species, demonstrate that osteoblasts have a characteristic PKC isozyme profile, including both phorbol ester-sensitive and -insensitive isozymes. The time course of down-regulation and the presence of phorbol-insensitive PKCs must be considered in interpreting the effects of phorbol esters on bone remodeling.
Insights
Osteoblasts express various protein kinase C (PKC) isozymes, with conventional and novel types down-regulated by phorbol esters, while atypical types remain unaffected. This characteristic PKC profile in bone cells is crucial for understanding phorbol ester effects on bone remodeling.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Protein Kinase C (PKC) is a crucial signal transducer in bone, influencing bone resorption.
- Phorbol esters are known to activate and down-regulate phorbol-sensitive PKC isozymes.
- Specific PKC isozyme roles in osteoblasts remain largely uncharacterized.
Purpose of the Study:
- To investigate the expression of various PKC isozymes in osteoblasts.
- To examine the phorbol ester-induced down-regulation of these PKC isozymes in osteoblasts.
Main Methods:
- Screened normal mouse osteoblasts and seven osteoblastic cell lines for PKC isozyme expression using Western immunoblotting with isozyme-specific antibodies.
- Treated normal osteoblasts and UMR-106 cells with phorbol 12, 13-dibutyrate (PDB) for varying durations to assess isozyme sensitivity.
- Analyzed down-regulation kinetics, dose-dependency, specificity, and reversibility of phorbol ester effects.
Main Results:
- Osteoblasts express conventional (alpha, beta I), novel (epsilon, delta, eta, theta), and atypical (zeta, iota/lambda) PKC isozymes.
- Prolonged phorbol ester treatment down-regulated conventional and novel PKC isozymes but not atypical ones.
- Novel delta and epsilon isozymes exhibited faster and more pronounced down-regulation compared to conventional isozymes.
Conclusions:
- Osteoblasts possess a distinct PKC isozyme profile, including both phorbol ester-sensitive and -insensitive forms.
- The differential sensitivity and expression of PKC isozymes are critical factors in bone cell signaling.
- Understanding this PKC profile is essential for interpreting the impact of phorbol esters on bone remodeling processes.